Published in Chem Biol on January 01, 2005
A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nat Biotechnol (2009) 2.49
Target identification using drug affinity responsive target stability (DARTS). Proc Natl Acad Sci U S A (2009) 2.40
Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action. Genome Biol (2010) 1.42
Biochemical suppression of small-molecule inhibitors: a strategy to identify inhibitor targets and signaling pathway components. Chem Biol (2006) 1.12
Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization. Antimicrob Agents Chemother (2009) 1.12
Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol Biochem Parasitol (2010) 1.06
Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy. PLoS Genet (2012) 0.96
High-content, image-based screening for drug targets in yeast. PLoS One (2010) 0.92
Opposing effects of target overexpression reveal drug mechanisms. Nat Commun (2014) 0.90
Identification and validation of protein targets of bioactive small molecules. Bioorg Med Chem (2011) 0.89
Discovering the targets of drugs via computational systems biology. J Biol Chem (2011) 0.86
Forward chemical genetics in yeast for discovery of chemical probes targeting metabolism. Molecules (2012) 0.84
Robustness and evolvability in natural chemical resistance: identification of novel systems properties, biochemical mechanisms and regulatory interactions. Mol Biosyst (2010) 0.84
Expanding the diversity of allosteric bcr-abl inhibitors. J Med Chem (2010) 0.83
Functional genomics to uncover drug mechanism of action. Nat Chem Biol (2015) 0.82
A genomewide overexpression screen identifies genes involved in the phosphatidylinositol 3-kinase pathway in the human protozoan parasite Entamoeba histolytica. Eukaryot Cell (2014) 0.81
Combining chemical genomics screens in yeast to reveal spectrum of effects of chemical inhibition of sphingolipid biosynthesis. BMC Microbiol (2009) 0.81
Involvement of the pleiotropic drug resistance response, protein kinase C signaling, and altered zinc homeostasis in resistance of Saccharomyces cerevisiae to diclofenac. Appl Environ Microbiol (2011) 0.80
Antiprion drugs as chemical tools to uncover mechanisms of prion propagation. Prion (2007) 0.80
The Mcm2-7 replicative helicase: a promising chemotherapeutic target. Biomed Res Int (2014) 0.79
A high-throughput screen for chemical inhibitors of exocytic transport in yeast. Chembiochem (2010) 0.78
Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae. Mol Biosyst (2014) 0.78
A genome-wide over-expression screen identifies genes involved in phagocytosis in the human protozoan parasite, Entamoeba histolytica. PLoS One (2012) 0.77
Efforts to make and apply humanized yeast. Brief Funct Genomics (2015) 0.77
A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis. Oncotarget (2016) 0.76
Examining the interactome of huperzine A by magnetic biopanning. PLoS One (2012) 0.76
Chemical genetics: reshaping biology through chemistry. HFSP J (2007) 0.75
Antibacterial photosensitization through activation of coproporphyrinogen oxidase. Proc Natl Acad Sci U S A (2017) 0.75
Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A (2002) 25.47
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Coordinated transcription of key pathways in the mouse by the circadian clock. Cell (2002) 14.07
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature (2007) 7.12
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
Adding new chemistries to the genetic code. Annu Rev Biochem (2010) 6.32
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97
Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A (2009) 5.86
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science (2010) 5.50
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
An expanded eukaryotic genetic code. Science (2003) 4.66
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
Addition of a photocrosslinking amino acid to the genetic code of Escherichiacoli. Proc Natl Acad Sci U S A (2002) 3.77
Genetic incorporation of unnatural amino acids into proteins in mammalian cells. Nat Methods (2007) 3.45
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Expanding the genetic code. Annu Rev Biophys Biomol Struct (2006) 3.36
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat Chem Biol (2008) 3.23
A stem cell-based approach to cartilage repair. Science (2012) 3.22
An enhanced system for unnatural amino acid mutagenesis in E. coli. J Mol Biol (2009) 3.20
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A (2008) 3.13
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol (2011) 2.91
Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli. J Am Chem Soc (2002) 2.88
Addition of the keto functional group to the genetic code of Escherichia coli. Proc Natl Acad Sci U S A (2002) 2.84
Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc Natl Acad Sci U S A (2009) 2.80
Expanding the genetic code. Angew Chem Int Ed Engl (2004) 2.78
Genomically recoded organisms expand biological functions. Science (2013) 2.73
mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science (2013) 2.71
In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol (2011) 2.69
Self-renewal of embryonic stem cells by a small molecule. Proc Natl Acad Sci U S A (2006) 2.65
An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A (2006) 2.51
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc Natl Acad Sci U S A (2003) 2.45
A chemical biology approach reveals period shortening of the mammalian circadian clock by specific inhibition of GSK-3beta. Proc Natl Acad Sci U S A (2008) 2.39
A chemical toolkit for proteins--an expanded genetic code. Nat Rev Mol Cell Biol (2006) 2.39
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
Recombinant expression of selectively sulfated proteins in Escherichia coli. Nat Biotechnol (2006) 2.31
Genome-wide functional analysis of human cell-cycle regulators. Proc Natl Acad Sci U S A (2006) 2.31
A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol (2006) 2.27
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol (2010) 2.26
Efficient incorporation of unnatural amino acids into proteins in Escherichia coli. Nat Methods (2006) 2.24
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res (2010) 2.20
Substrate recognition by the AAA+ chaperone ClpB. Nat Struct Mol Biol (2004) 2.19
Oxysterols direct immune cell migration via EBI2. Nature (2011) 2.19
High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov (2008) 2.12
An expanded genetic code with a functional quadruplet codon. Proc Natl Acad Sci U S A (2004) 2.09
Synthetic small molecules that control stem cell fate. Proc Natl Acad Sci U S A (2003) 2.06
Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe (2012) 2.05
A facile system for encoding unnatural amino acids in mammalian cells. Angew Chem Int Ed Engl (2009) 2.02
The evolving war on cancer. Cell (2011) 2.02
Control of protein phosphorylation with a genetically encoded photocaged amino acid. Nat Chem Biol (2007) 1.99
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A (2012) 1.99
Identification of small molecule activators of cryptochrome. Science (2012) 1.95
A role for chemistry in stem cell biology. Nat Biotechnol (2004) 1.95
Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res (2010) 1.94
A genetically encoded fluorescent amino acid. J Am Chem Soc (2006) 1.93
The site-specific incorporation of p-iodo-L-phenylalanine into proteins for structure determination. Nat Biotechnol (2004) 1.93
Adding amino acids with novel reactivity to the genetic code of Saccharomyces cerevisiae. J Am Chem Soc (2003) 1.93
Exploring the limits of codon and anticodon size. Chem Biol (2002) 1.89
A public-private partnership to unlock the untargeted kinome. Nat Chem Biol (2013) 1.83
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell (2012) 1.81
Developing irreversible inhibitors of the protein kinase cysteinome. Chem Biol (2013) 1.81
A combinatorial scaffold approach toward kinase-directed heterocycle libraries. J Am Chem Soc (2002) 1.79
Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex. Science (2008) 1.79
A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A (2006) 1.78
A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell (2009) 1.78
A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A (2014) 1.77
Directed evolution of the site specificity of Cre recombinase. Proc Natl Acad Sci U S A (2002) 1.77
Profiling protein function with small molecule microarrays. Proc Natl Acad Sci U S A (2002) 1.77